Cover Image
市場調查報告書

臨床檢驗服務市場趨勢、預測:亞太地區版

Medical Laboratory Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department. 2016 to 2019 - Asia Pacific Version

出版商 Howe Sound Research 商品編碼 358168
出版日期 內容資訊 英文 259 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
臨床檢驗服務市場趨勢、預測:亞太地區版 Medical Laboratory Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department. 2016 to 2019 - Asia Pacific Version
出版日期: 2016年10月17日 內容資訊: 英文 259 Pages
簡介

本報告提供亞太地區的各種臨床檢驗服務的市場調查,產業結構和價值鏈,市場成長的各種影響因素分析,技術的發展趨勢,企業及企業間的配合措施,主要企業簡介,各國家、檢驗種類的市場規模的變化與預測等彙整資料。

第1章 簡介、市場定義

第2章 市場概要

  • 相關經營者、組織
    • 供應商 (醫藥品)
    • 獨立型實驗室 (專門、特殊領域)
    • 獨立型實驗室 (國家、地方政府系)
    • 獨立型實驗室 (分析)
    • 國家、地方政府系公共實驗室
    • 醫院實驗室
    • 醫生的實驗室
    • 審核團體
  • 市場區隔
  • 產業結構
  • 主要企業簡介
  • 各國家、地區的多樣性

第3章 市場趨勢

  • 促進成長要素
  • 阻礙成長要素
  • 自動化
  • 環境與演進
  • 診斷技術的發展

第4章 臨床檢驗、分子診斷、基因診斷的近幾年的發展趨勢

  • 最新趨勢:發展的重要性和本章的活用方法
  • Quest Diagnostics:收購臨床實驗室合作夥伴
  • Illumina、Almac:在NGS CDx化驗上合作
  • Rite Aid:向消費者提供Harmonyx的遺傳基因檢驗
  • Singulex:生物標記的用途擴大上取得美國專利技術等

第7章 市場分析:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他
    • 臨床化學檢驗:數量、價格、收益
    • 微生物學的檢驗:數量、價格、收益
    • 血液檢驗:數量、價格、收益
    • 解剖病身體檢查:數量、價格、收益
    • 分子診斷:數量、價格、收益
    • 全臨床檢驗:數量、價格、收益
    • 心臟生物標記:數量、價格、收益
    • 分子診斷 (腫瘤):數量、價格、收益
    • 分子診斷 (遺傳):數量、價格、收益

第10章 臨床實驗室的未來性

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • changing demographics
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • automation

Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

" Medical Laboratory Testing Services.

Strategies & Trends. Volume & Price Forecasts by Laboratory Department.

2016 to 2019 - Asia Pacific Version" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Order an Enterprise Version specifically customized for your organizations needs for distribution throughout your company.

Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges. Questions? Email us at service at howesoundresearch.com. We would be glad to let you know if we can be of help.

The report includes detailed breakouts for 5 Countries and 1 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Introduction and Market Definition

  • 1.1 Introduction
  • 1.2 Market Definition
    • 1.2.1 Volumes
    • 1.2.2 Prices
    • 1.2.3 Revenue Market Size
  • 1.3 Methodology
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.3.1 U.S. Medicare Expenditures for Clinical Testing

2. Market Overview

  • 2.1 Market Participants
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab.
    • 2.1.7 Physician lab.
    • 2.1.8 Audit body
  • 2.2 Market Segments
    • 2.2.1 Traditional Market Segmentation
    • 2.2.2 Laboratory Focus and Segmentation
  • 2.3 Industry Structure
    • 2.3.1 Hospital Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT.
  • 2.4 Profiles of Key Companies
    • 2.4.1 Quest Diagnostics
    • 2.4.2 Laboratory Corporation of America
    • 2.4.3 Lifelabs Medical Laboratory Services
    • 2.4.4 ACM Medical Laboratory
    • 2.4.5 Spectra Spectra Laboratories, Inc.
    • 2.4.6 Bio-Reference Laboratories, Inc.
    • 2.4.7 Signal Genetics LLC
    • 2.4.8 CompuNet Clinical Laboratories, LLC
    • 2.4.9 Genzyme Corporation
    • 2.4.10 Sonic Healthcare Limited
    • 2.4.11 Exagen Diagnostics, Inc.
    • 2.4.12 Clongen Laboratories LLC
    • 2.4.13 Clinical Reference Laboratory, Inc.
    • 2.4.14 Rosetta Genomics Inc.
    • 2.4.15 Mid America Clinical Laboratories, LLC
    • 2.4.16 Alere Inc
    • 2.4.17 Caris Life Sciences, Inc.
    • 2.4.18 Psychemedics Corp.
    • 2.4.19 Aurora Diagnostics, LLC
    • 2.4.20 DL Reference Laboratory
    • 2.4.21 Myriad Genetics, Inc.
    • 2.4.22 Bioscientia Institut fuer Medizinische Diagnostik GmbH
    • 2.4.23 Acibadem Labmed Laboratory
    • 2.4.24 Claymon Biomnis Laboratories Ltd.
    • 2.4.25 Biomnis (France)
    • 2.4.26 The Doctor's Laboratory (Sonic Healthcare U.K.)
    • 2.4.27 Pathology Inc.
    • 2.4.28 Gribbles Pathology
    • 2.4.29 BP Lab
    • 2.4.30 Adicon Clinical Laboratories, Inc.
    • 2.4.31 Diagnósticos da América (DASA)
    • 2.4.32 Medicus Phillipines Inc.
    • 2.4.33 Kingmed Diagnostics
    • 2.4.34 Ascend Clinical, LLC
    • 2.4.35 Unilabs SA
    • 2.4.36 American Pathology Partners, Inc.
    • 2.4.37 Centrex Clinical Laboratories, Inc.
    • 2.4.38 Integrated Regional Laboratories, Inc.
    • 2.4.39 Vira Cor-Ibt Laboratories
    • 2.4.40 Clarient, Inc.
    • 2.4.41 Genomic Health, Inc.
    • 2.4.42 ARUP Laboratories, Inc.
    • 2.4.43 MEDTOX Scientific, Inc.
    • 2.4.44 Solstas Lab Partners
    • 2.4.45 Predictive Biosciences, Inc.
    • 2.4.46 Enzo Biochem, Inc.
  • 2.5 National and Regional Diversity

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Impact of U.S. Health Reform (PPACA) on U.S. Market
    • 3.1.2 Understanding the Impact of Aging Population.
    • 3.1.3 Economic growth drives health spending.
    • 3.1.4 Point of Care Testing can increase demand
    • 3.1.5 Wellness concerns create growth
    • 3.1.6 Esoteric Testing Moving Mainstream
    • 3.1.7 Genetic Based Testing Creates New Department and New Discipline
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower costs trend to continue
    • 3.2.2 Economic or population contraction
    • 3.2.3 Testing usage analysis curtailing growth
    • 3.2.4 Wellness has a downside
    • 3.2.5 Test Displacement Impacts Important
    • 3.2.6 Point of Care Testing
  • 3.3 Automation
    • 3.3.1 Stranded LIMS Investment
    • 3.3.2 Software as a Service
    • 3.3.3 Physician Office and Access Systems
  • 3.4 Environment and Evolution
  • 3.5 Diagnostic Technology Development
    • 3.5.1 Next Generation Sequencing Fuels a Revolution
    • 3.5.2 Impact of NGS on pricing
    • 3.5.3 POCT/Self Testing Disruptive Force
    • 3.5.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.5.5 CGES Testing, A Brave New World.
    • 3.5.6 Molecular Diagnostics Technologies At The Forefront of Growth
    • 3.5.7 Biochips/Giant magneto resistance based assay

4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • 4.2 Quest Diagnostics to Acquire Clinical Laboratory Partners
  • 4.3 Illumina, Almac to Collaborate on NGS CDx Assays
  • 4.4 Rite Aid First U.S. Drugstore Chain to Offer Harmonyx Genetic Testing to Customers
  • 4.5 US Patent Awarded to Singulex for Expanded Use of Biomarkers
  • 4.6 Feds to scrutinize med tech Medicare reimbursement in fiscal 2016
  • 4.7 Trovagene's Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study
  • 4.8 Roche Rapid Flu MDx Test Shown to Impact Patient Care in ER
  • 4.9 CareDx Mobilizing Response Team After CMS Initial AlloMap Pricing Threatens Business
  • 4.10 PTS Diagnostics' Patent Enforcement Against Jant Pharmacal Gains Momentum
  • 4.11 SeraCare Life Sciences Announces Early Access Programs for ctDNA and RNA Fusion Reference Materials
  • 4.12 Eurofins Acquires Diatherix to Strengthen Specialty Clinical Diagnostics Focus
  • 4.13 Abbott Laboratories to buy St. Jude Medical for $25 billion
  • 4.14 CombiMatrix Gets Serious About Potential M&A Options in Wake of $8M Offering
  • 4.15 Abbott to Acquire Alere, Becoming Leader in Point of Care Testing
  • 4.16 Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger
  • 4.17 LabCorp Agrees to Acquire Assets of Pathology Inc.
  • 4.18 NeoGenomics Completes Acquisition of Clarient, Inc.
  • 4.19 FDA Gets Pushback on Move to Regulate Lab Developed Tests
  • 4.20 Cancer Genetics, Inc. Announces Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry
  • 4.21 Theranos plans to close all its clinical labs and lay off about 340 workers.
  • 4.22 Forte Capital Lowers stake in Laboratory Corp. of America Holdings
  • 4.23 The US Oncology Network Selects Myriad Genetics As Preferred Provider For Hereditary Cancer Testing
  • 4.24 Pyxant Labs Commences Clinical Laboratory Testing Services
  • 4.25 Viewics Launches Diabetes Management (vCAT), A Free Solution For Laboratories Providing Powerful Diabetes Population Management Analytics To Healthcare Organizations
  • 4.26 Alpha Genomix And Rx30 Partner To Provide Personalized Medication Therapy
  • 4.27 LabCorp Doubles The Testing Capacity Of Covance Central Laboratory In Geneva
  • 4.47 OpGen Files for IPO for up to $37M
  • 4.48 Transgenomic Closes Public Offering of Stock, Warrants
  • 4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
  • 4.50 Laboratory Corporation of America Holdings Full Year Results
  • 4.51 GenomeDx Biosciences Implements Clarity LIMS
  • 4.52 Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.53 Lifecode Receives CAP Accreditation, Discloses Funding
  • 4.54 Baylor College of Medicin, Miraca Holdings finalize joint venture
  • 4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
  • 4.56 LabCorp to Buy Covance for $6.1 Billion to Add Drug R&D
  • 4.57 Trinity Biotech Revenues Grow by 15%
  • 4.58 Google's Latest Healthcare Initiative
  • 4.59 Trinity Biotech Announces US Clinical Trials
  • 4.60 Agena Bioscience Launches Smaller Format MassArray
  • 4.61 QuantRx® Biomedical Provides Update on Technological Progress
  • 4.62 The Journal of Molecular Diagnostics Publishes Special Article
  • 4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
  • 4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
  • 4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
  • 4.66 Nuclea Bio Plans Entry into Clinical Proteomics
  • 4.67 Personal Genome Diagnostics Aims for FDA Clearance
  • 4.68 Enzo Biochem Announces New Molecular Platform
  • 4.69 Multiplicom, Premaitha Develop CE-IVDs
  • 4.70 Regulating the Next Generation of Genetic Testing
  • 4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
  • 4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
  • 4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
  • 4.74 Accelerate Diagnostics' 2014 Revenues Rise Sharply
  • 4.75 NanoString's Q4 Revenues Jump 54 Percent
  • 4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
  • 4.77 HTG Molecular Reports 50 Percent Increase in 2014 Revenues
  • 4.79 LabCorp Posts 5 Percent Revenue Growth
  • 4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
  • 4.81 ACT Genomics Raises $8M in Private Funding Round
  • 4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
  • 4.83 Invitae Goes Public with $101.6M Offering
  • 4.84 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
  • 4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
  • 4.86 Premaitha Iona NIPT Lands CE Mark
  • 4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
  • 4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
  • 4.89 Invitae Amends IPO Filing Targeting up to $92.3M
  • 4.90 Biofortuna Closes $2.2M Funding Round
  • 4.91 Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
  • 4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
  • 4.93 BioMerieux 2014 Revenues Increase 7 Percent
  • 4.94 Cypher Genomics and Sequenom Announce Development Agreement
  • 4.95 Abcam to Acquire Firefly BioWorks for $28M
  • 4.96 PerkinElmer Opens Medical Laboratory in China
  • 4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
  • 4.98 GenMark Projects 52 Percent Growth in Q4 Revenues
  • 4.99 Amarantus Acquires DioGenix for up to $10.9M
  • 4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
  • 4.101 DiaCarta Raises $8M in Series A Round
  • 4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
  • 4.103 Adaptive Biotechnologies Acquires Sequenta
  • 4.104 Aegis Sciences Acquires MDx Firm Diagnovus

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.1.2 Microbiology - Volumes, Prices, Revenues
    • 7.1.3 Hematology - Volumes, Prices, Revenues
    • 7.1.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.1.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.1.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.1.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.1.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.1.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.2.2 Microbiology - Volumes, Prices, Revenues
    • 7.2.3 Hematology - Volumes, Prices, Revenues
    • 7.2.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.2.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.2.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.2.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.2.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.2.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.3.2 Microbiology - Volumes, Prices, Revenues
    • 7.3.3 Hematology - Volumes, Prices, Revenues
    • 7.3.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.3.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.3.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.3.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.3.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.3.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.4.2 Microbiology - Volumes, Prices, Revenues
    • 5.1.3 Hematology - Volumes, Prices, Revenues
    • 7.4.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.4.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.4.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.4.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.4.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.4.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.5.2 Microbiology - Volumes, Prices, Revenues
    • 7.5.3 Hematology - Volumes, Prices, Revenues
    • 7.5.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.5.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.5.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.5.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.5.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.5.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Clinical Chemistry - Volumes, Prices, Revenues
    • 7.6.2 Microbiology - Volumes, Prices, Revenues
    • 7.6.3 Hematology - Volumes, Prices, Revenues
    • 7.6.4 Anatomic Pathology - Volumes, Prices, Revenues
    • 7.6.5 Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.6.6 All Clinical Testing - Volumes, Prices, Revenues
    • 7.6.7 Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.6.8 Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.6.9 Molecular Diagnostic Genetics - Volumes, Prices, Revenues

10. The Future of the Clinical Laboratory

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Clinical Laboratory Departments and Segments
  • Table 4 Laboratory Management Focus - Different Approaches
  • Table 5 Key Segmentation Variables Going Forward
  • Table 6 Factors Affecting Local Clinical Testing Demand
  • Table 7 Seven Factors Driving Growth
  • Table 8 Six Factors Limiting Growth
  • Table 9 Key Diagnostic Laboratory Technology Trends.
  • Table 10 Next Generation Sequencing Technologies - Speed and Cost
  • Table 11 Key Point of Care Testing Uses
  • Table 12 Clinical Application Areas for Molecular Diagnostics
  • Table 13 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 14 Microbiology - Volume Price and Revenue Forecast
  • Table 15 Hematology - Volume Price and Revenue Forecast
  • Table 16 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 17 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 18 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 19 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 20 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 21 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 22 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 23 Microbiology - Volume Price and Revenue Forecast
  • Table 24 Hematology - Volume Price and Revenue Forecast
  • Table 25 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 26 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 27 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 28 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 29 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 30 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 31 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 32 Microbiology - Volume Price and Revenue Forecast
  • Table 33 Hematology - Volume Price and Revenue Forecast
  • Table 34 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 35 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 36 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 37 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 38 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 39 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 40 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 41 Microbiology - Volume Price and Revenue Forecast
  • Table 42 Hematology - Volume Price and Revenue Forecast
  • Table 43 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 44 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 45 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 46 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 47 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 48 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 49 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 50 Microbiology - Volume Price and Revenue Forecast
  • Table 51 Hematology - Volume Price and Revenue Forecast
  • Table 52 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 53 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 54 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 55 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 56 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 57 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 58 Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 59 Microbiology - Volume Price and Revenue Forecast
  • Table 60 Hematology - Volume Price and Revenue Forecast
  • Table 61 Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 62 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 63 All Clinical Testing - Volume Price and Revenue Forecast
  • Table 64 Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 65 Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 66 Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 67 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
Back to Top